The prevalence of obesity in the United States could rise sharply under a new definition of obesity released earlier this year by the Lancet Diabetes and Endocrinology Commission. Researchers… read more.
A register-based study from Finland identified three distinct BMI trajectory groups among patients with newly diagnosed type 2 diabetes. In a four-year follow-up, most patients followed a stable… read more.
Obesity is associated with worse flare symptoms and worse quality of life among patients with early rheumatoid arthritis, researchers reported on Nov. 12, 2023 at ACR Convergence 2023,… read more.
A new study by Uppsala University shows that a higher body mass index (BMI) increases the risk of five different rheumatic diseases: rheumatism, osteoarthritis, gout, psoriatic arthritis and… read more.
The make-up and volume of gut bacteria in toddlers at 3.5 years old is predictive of body mass index (BMI) at age 5, irrespective of whether they are… read more.
For patients with higher body mass index (BMI) undergoing unicompartmental or “partial” knee replacement (UKR), long-term outcomes are improved when the implant is placed using a cementless rather… read more.
With one in four adults estimated to be obese in the UK, and growing numbers of children affected, obesity is a global health challenge. While the dangers of… read more.
Though obesity in midlife is linked to an increased risk for Alzheimer’s disease, new research suggests that a high body mass index later in life doesn’t necessarily translate… read more.
Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).
Tesaro has submitted a supplemental New Drug Application (sNDA) to the FDA for Zejula (niraparib). The application was granted priority review and has an action date of 24 October 2019.
Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).
This article summarises some of the key study updates presented at DDW 2018.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
